Recruiting
Who can join AIPeople with Primary Hyperoxaluria Type 1 (PH1).
What is being studied AITests safety, tolerability, pharmacokinetics, and effects of a single IV dose of YOLT-203.
Study typeTreatment (drug) · Phase 1
CountriesChina
Primary Hyperoxaluria
Browse recruiting and upcoming clinical trials for primary hyperoxaluria.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Recruiting
Who can join AIPeople aged 6 years and older with genetically confirmed Primary Hyperoxaluria Type 1 (PH1).
What is being studied AITests a single-dose gene-editing infusion (YOLT-203) versus placebo for PH1.
Study typeTreatment (drug) · Phase 2
CountriesUnited States
Recruiting
Who can join AIPeople aged 6–64 with genetically confirmed primary hyperoxaluria type 1 (AGXT) meeting specified kidney, urine oxalate, and weight limits.
What is being studied AITests safety, dosing, and biological effects of a single IV dose of ABO-101.
Study typeTreatment (drug) · Phase 1/2
CountriesFrance, Germany, Tunisia +2
Recruiting
Who can join AIPeople aged ≥2 years with genetically confirmed Type 1 Primary Hyperoxaluria (PH1) who meet kidney and urine-oxalate criteria.
What is being studied AITests safety, tolerability, PK/PD and effect of a single IV dose of YOLT-203 on oxalate.
Study typeTreatment (drug) · Early Phase 1
CountriesChina
Recruiting
Who can join AIPeople with primary hyperoxaluria type 1 (PH1) who have severe renal impairment or end‑stage renal disease (with or without dialysis).
What is being studied AITests monthly DCR-PHXC for safety and effects on plasma oxalate in PH1 with ESRD.
Study typeTreatment (drug) · Phase 2
CountriesFrance, Germany, Italy +7
Not yet recruiting
Who can join AIPeople aged 6 years and older with genetically confirmed primary hyperoxaluria type 1, 2, or 3.
What is being studied AITests whether stiripentol changes 24-hour urinary oxalate compared with placebo and assesses safety.
Study typeTreatment (drug) · Phase 3
CountriesNot posted yet
Recruiting
Who can join AIPeople of any age with primary hyperoxaluria type 1 who have been treated with lumasiran in France.
What is being studied AICollects urine and clinical data to track oxaluria and PH1 course before and after lumasiran.
Study typeObservational
CountriesFrance
Recruiting
Monogenic Kidney Stone - Genetic Testing
NCT03305835
Who can join AIPeople with rare or suspected monogenic kidney stone diseases and their family members.
What is being studied AIGenetic testing and collection of DNA and clinical stone-history information.
Study typeObservational
CountriesUnited States
Recruiting
Who can join AIPeople with primary or enteric hyperoxaluria, cystinuria, Dent disease (including carriers), Lowe syndrome, or APRT deficiency.
What is being studied AICollects clinical data and blood/urine inflammatory markers over time.
Study typeObservational
CountriesCanada, Iceland, Israel +1
Recruiting
Rare Kidney Stone Consortium Biobank
NCT02026388
Who can join AIPeople with primary hyperoxaluria, Dent disease, APRT deficiency, or cystinuria — and their family members.
What is being studied AICollects and stores biologic samples for future research.
Study typeObservational
CountriesUnited States
Recruiting
Who can join AIPeople with Primary Hyperoxaluria, Dent disease, Cystinuria, or APRT deficiency.
What is being studied AICollects medical and clinical data into a registry for these hereditary kidney stone diseases.
Study typeObservational
CountriesIceland, United States
Recruiting
National Registry of Rare Kidney Diseases
NCT06065852
Who can join AIChildren and people with one of the many rare kidney diseases listed in this registry.
What is being studied AICollects clinical data, patient-reported outcomes, and samples to support research.
Study typeRegistry
CountriesUnited Kingdom
Trials that may include primary hyperoxaluria (1)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Recruiting
Who can join AIAdults (≥18 years) with papulopustular rosacea (PPR).
What is being studied AITests remibrutinib versus placebo for reducing inflammatory lesions in papulopustular rosacea.
Study typeTreatment (drug) · Phase 2
CountriesCanada, China, Singapore +2